BTRX 335140 CAS 2244614-14-8

BTRX 335140 CAS 2244614-14-8, also known as Navacaprant, primarily targets the central nervous system's role in mood and cognitive regulation. This substance acts with high selectivity on κ-opioid receptors, exhibiting potent affinity for its target site, while displaying extremely low cross-activity with μ and δ-opioid receptors. Therefore, it possesses a significant advantage in its mechanism of action, avoiding the adverse reaction risks commonly associated with traditional related substances. Its mechanism of action mainly involves regulating the dynorphin-KOR signaling system, improving the function of reward, motivation, and mood regulation circuits in the brain, particularly targeting key manifestations such as depressed mood and loss of interest. It possesses good blood-brain barrier penetration and stable absorption characteristics, maintaining a stable effect with once-daily administration.

In early clinical studies, BTRX-335140 demonstrated positive effects and good tolerability, becoming a highly anticipated investigational project in this area of ​​mechanism of action. Although key later studies did not achieve the expected goals, hindering its progress in the main direction, the substance continues to be explored in the field of bipolar mood and provides important clinical references and experience for the subsequent research and development of similar mechanisms, which is of landmark significance in the field of research and development of small molecules with central nervous system activity.